Chargement des cours...
Prévisions
L'objectif de cours moyen des analystes est de 8,44 € (+6,03 %). La médiane est de 8,17 € (+2,64 %).
| Acheter |
15 |
| Conserver |
27 |
| Vendre |
0 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
BetterHelp and Sophia Bush launch The Permission Project to address women's mental health
BetterHelp launched The Permission Project, a therapist-developed initiative partnered with Sophia Bush that provides a Rewrite Guide, 10,000 hours of free therapy and a $100,000 investment in therapists focused on women’s mental health. The program is based on research identifying social tensions—like being ambitious but likeable—that correlate with rising anxiety and depression among women and offers actionable steps to counter them. Bush, who contributed to the project, emphasizes systemic causes of women's unrecognized labor and the need for cultural change alongside individual support. » Plus sur forbes.com
Teladoc Health appoints Michael Grasher as chief financial officer
Teladoc Health has appointed Michael Grasher as CFO, effective immediately. Grasher has more than 30 years of experience in the insurance and financial services sector, including over 12 years in CFO roles at companies such as IFG Companies, Fortegra and AMERISAFE, and he also spent many years in equity research. » Plus sur de.investing.com
Teladoc Health appoints Mark V. Anquillare to the board of directors
Teladoc Health has appointed Mark V. Anquillare, former president and COO of Verisk Analytics, to its board of directors. He will serve on the audit and compensation committees and brings more than 30 years of experience in finance and leadership roles, including overseeing Verisk’s 2009 IPO. Anquillare also sits on several other boards; Teladoc Health provides virtual healthcare services through partnerships with insurers, employers and health systems. » Plus sur de.investing.com
Teladoc reports revenue decline and cuts annual forecast – stock falls sharply
Teladoc reported Q2 revenue of $606.9 million, missing the analyst consensus of about $615 million, while adjusted EPS of -$0.21 beat expectations. Consumer segment BetterHelp shrank 12% to $212.6 million. For Q3 management expects revenue of $569–609 million and lowered the full-year guidance to $2.36–2.45 billion (previously $2.48–2.58 billion), which weighed heavily on the stock in premarket trading. CEO Chuck Divita cited provider capacity constraints as the reason for weaker revenue realization; over the past six months there have been only insider sales. » Plus sur de.investing.com
Teladoc plunges about 24% after Q2 results and weak outlook
Teladoc reported a Q2 EPS loss of -$0.21 with revenue of $606.9 million, missing consensus. The Q3 outlook of $569–609 million is well below the $629 million consensus, and the full-year loss forecast was lowered to -$1.00 to -$0.75. The combination of a revenue miss, reduced guidance and continued drag from the BetterHelp segment triggered the sharp share decline. Investors are now awaiting management comments on the conference call for signs of a return to revenue growth. » Plus sur de.investing.com
Dividendes historiques Dividendes
Tous les indicateurs de dividendes Tous les indicateursDonnées financières de l'entreprise
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 534,21 M | 0,08 % |
| Bénéfice brut | 366,25 M | 2,15 % |
| Bénéfice net | -23,78 M | 43,63 % |
| EBITDA | 61,03 M | 54,17 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 1,46 Md € |
Nombre d'actions | 182,29 M |
Plus haut/bas sur 52 semaines | 8,98 € - 3,99 € |
| Dividendes | Non |
Bêta | 1,97 |
Ratio P/E | -10,25 |
Ratio PEG | -0,25 |
Ratio P/B | 1,24 |
Ratio P/S | 0,65 |
Profil de l'entreprise
Teladoc Health, Inc. fournit des services de soins de santé virtuels aux États-Unis et à l'international. La société propose un portefeuille de services et de solutions couvrant les affections médicales non urgentes, ponctuelles, chroniques et complexes, notamment le diabète, l'hypertension, la maladie rénale chronique, le cancer, l'insuffisance cardiaque congestive et les troubles de santé mentale. Elle offre une gamme de programmes et de services, comprenant des solutions de télésanté en médecine générale et en médecine spécialisée, la gestion des maladies chroniques, des services médicaux experts, des solutions de santé mentale, ainsi que des services de plateforme et de programmes. La société s'adresse aux employeurs, aux régimes de santé, aux hôpitaux et systèmes hospitaliers, ainsi qu'aux compagnies d'assurance et de services financiers, de même qu'aux membres individuels. Elle commercialise ses produits et services sous les marques Teladoc, Livongo et BetterHelp. La société était auparavant connue sous le nom de Teladoc, Inc. et a changé sa dénomination en Teladoc Health, Inc. en août 2018. La société a été constituée en 2002 et son siège social se situe à Purchase, dans l'État de New York.
| Nom | Teladoc Health |
| PDG | Charles Divita |
| Siège social | New York,
ny États-Unis |
| Site web | |
| Secteur | Santé |
| Industrie | Prestataires et services de santé |
| Introduction en bourse | 30/06/2015 |
| Employés | 5 124 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NYSE | TDOC |
London Stock Exchange | 0LDR.L |
XETRA | 4LL.F |
Frankfurt | 4LL.F |
Düsseldorf | 4LL.DU |
London | 0LDR.L |
SIX | 4LL.SW |
München | 4LL.MU |